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Workers in nuclear plants are at potential risk of exposure to
ionizing radiations, both externally from radioactivity in the
working environment and internally from radionuclides which
enter the body by inhalation, ingestion or through accidents
resulting in percutaneous wounds. The possible carcinogenic
effects of exposure to external sources of radiation among nuclear
workers have been the subject of a large number of studies
(Kendall et al, 1992; Gilbert et al, 1993; Carpenter et al, 1994;
Cardis et al, 1995), but there have been few studies of internal
exposure to radionuclides among these groups. We have reported
previously on mortality and cancer morbidity among workers at
the Sellafield plant of British Nuclear Fuels (BNFL) (Smith and
Douglas, 1986; Douglas et al, 1994). We examined possible risks
associated with exposure to external radiation, but at these times
the data available on exposure to radionuclides were inadequate
for detailed analysis. Among workers at the Sellafield plant, the
element of most concern is plutonium. More workers are poten-
tially exposed to the isotopes of plutonium than other radionu-
clides and the contribution of plutonium exposure to the collective
internal dose is far greater than that of other radionuclides (Riddell
et al, 1998).
Exposure to external radiation involves relatively uniform expo-
sure of a worker to sparsely ionizing, penetrating radiation.
Plutonium emits alpha particles which traverse only a few cells
before coming to a halt. It is a biological hazard, therefore, when
taken into the body, in which the alpha particles irradiate those
cells close to where the plutonium is deposited. Plutonium is
physically long-lived and also is retained in the body with a long
biological half-life, so that it delivers its dose to adjacent tissues
over a long period of time. The biochemistry of plutonium is such
that it is generally concentrated in particular parts of the body and
this leads to a heterogeneous distribution of the dose from pluto-
nium. Plutonium concentrates, principally, in the liver and in the
skeleton, so that the risk of cancer through exposure to plutonium
is likely to be greatest for the lung (if inhaled), liver, bone and,
possibly, leukaemia. Densely ionizing alpha particles cause more
biological damage than sparsely ionizing radiations and a
weighting factor of 20 is applied to the absorbed doses to generate
equivalent doses (Committee on Biological Effects of Ionizing
Radiations, 1988; Clarke et al, 1996).
The Sellafield plant, on the Cumbrian coast in the UK, was
developed originally for the production of plutonium for nuclear
weapons. Later, plutonium was produced as a consequence of the
commercial reprocessing of spent nuclear fuel and has been stored
on the site. Workers have been monitored for possible exposure to
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Summary The mortality of all 14 319 workers employed at the Sellafield plant of British Nuclear Fuels between 1947 and 1975 was studied
up to the end of 1992, and cancer incidence was examined from 1971 to 1986, in relation to their exposures to plutonium and to external
radiation. The cancer mortality rate was 5% lower than that of England and Wales and 3% less than that of Cumbria. The significant excesses
of deaths from cancer of the pleura and thyroid found in an earlier study persist with further follow-up (14 observed, 4.0 expected for pleura;
6 observed, 2.2 expected for thyroid). All of the deaths from pleural cancer were among radiation workers. For neither site was there a
significant association between the risk of the cancer and accumulated radiation dose. There were significant deficits of deaths from cancers
of mouth and pharynx, liver and gall bladder, and larynx and leukaemia when compared with the national rates. Among all radiation workers,
there was a significant positive association between accumulated external radiation dose and mortality from cancers of ill-defined and
secondary sites (10-year lag, P = 0.04), leukaemia (no lag, P = 0.03; 2-year lag, P = 0.05), multiple myeloma (20-year lag, P = 0.02), all
lymphatic and haematopoietic cancers (20-year lag, P = 0.03) and all causes of death combined (20-year lag, P = 0.008). Among plutonium
workers, there were significant excesses of deaths from cancer of the breast (6 observed, 2.6 expected) and ill-defined and secondary
cancers (29 observed, 20.1 expected). No significant positive trends were observed between the risk of deaths from cancers of any specific
site, or all cancers combined, and cumulative plutonium and external radiation doses. For no cancer site was there a significant excess of
cancer registrations compared with rates for England and Wales. Analysis of trends in cancer incidence showed significant increases in risk
with cumulative plutonium plus external radiation doses for all lymphatic and haematopoietic neoplasms for 0-, 10- and 20-year lag periods.
Taken as a whole, our findings do not suggest that workers at Sellafield who have been exposed to plutonium are at an overall significantly
increased risk of cancer compared with other radiation workers.
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plutonium since it was first produced in the plant. The most likely
route of exposure has been through inhalation, and monitoring has
been conducted principally through the analysis of urine samples
collected from workers. These monitoring data have been assem-
bled comprehensively by BNFL and estimates have been made of
plutonium uptake for individual workers for each year during
which they may have been exposed. These uptake estimates have
been used further to estimate annual radiation doses to specific
organs where plutonium might be deposited (Riddell et al, 1998).
We have related these dose estimates to cancer mortality and
morbidity in the work force since construction of the plant started
in 1947.
POPULATION AND METHODS
We have described previously the study population, the nature and
source of external radiation exposure data and the methods used to
determine the vital status, causes of death and cancer registrations
(Smith and Douglas, 1986; Douglas et al, 1994). We summarize
this information briefly below, together with the details of pluto-
nium exposure and the methods used to derive estimates of pluto-
nium uptake and organ-specific doses.
Study population
The study population consisted of all workers (14 385) employed
by BNFL or its predecessors at the Sellafield plant at any time
between the date it opened, in 1947, and 1 January 1976. In our
previous paper, the number of such workers was given as 14 282
(Douglas et al, 1994). Subsequent investigations made by BNFL
staff, using personnel and plant medical records, resulted in the
exclusion of six persons who were working at another BNFL plant
and one who had been incorrectly included in the study twice.
Records of a further 110 workers were also discovered who should
have been included in the study population. Most of these were
employed during the early years of the plant￿s operation.
Follow-up
For the analyses reported in this paper, follow-up of the study
population was extended from 1 January 1989 (Douglas et al,
1994) to 1 January 1993. For all workers whose dates of birth and
sex were known, an attempt was made to trace their vital status
through the National Health Service Central Registers (NHSCRs).
Information on cancer registrations was derived from the same
source. Of the 14 319 (99.5%) workers with known date of birth
and sex, 9937 (69.4%) were traced as alive on 1 January 1993,
3854 (26.9%) had died, 491 (3.4%) were known to have emigrated
and 35 (0.2%) could not be traced (Table 1). Workers in the last
two groups were included in the analyses up to their dates of
emigration or last employment at the plant, respectively. Death
certificates were obtained for each worker who had died and the
underlying cause of death recorded was coded according to the
International Classification of Diseases and Causes of Death
(ICD) in operation at the time of death.
The coverage of the national cancer registration scheme was
reasonably complete only by 1971 and, therefore, analyses of
Table 1 Study population at 1 January 1993
Men (%) Women (%) Total (%)
Total number of workers 11 679 (100.0) 2689 (100.0) 14 385 (100.0)
No. for whom date of birth not known 44 (0.4) 5 (0.2) 66a (0.5)
No. eligible for analysis 11 635 (99.6) 2684 (99.8) 14 319 (99.5)
Alive 1 January 1993 7 800 (66.8) 2137 (79.5) 9937 (69.1)
Died before 1993 3411 (29.2) 445 (16.5) 3854 (26.8)
Emigrated 401 (3.4) 90 (3.3) 491 (3.4)
Untraced 23 (0.2) 12 (0.5) 35 (0.2)
Total years of follow-up 332 532.4 82 899.3 415 431.6
Average duration of follow-up (years) 28.6 30.9 29.0
aIncludes 17 of unknown sex.
Table 2 Estimated cumulative collective radiation doses from external
radiation and from plutonium exposure
External radiation
Total cumulative dose (mSv)
All radiation workers (n = 10 382) 1 352 326
All plutonium workers (n = 5203) 1 023 534
Plutonium workers with plutonium dose 958 868
assessed (n = 4609)
Plutonium exposure
Cumulative organ dose (mSv)b
Organ ‘W’ ‘Y’
Bone surfaces 3 282 100
Lungs 44 576 896 177
Red bone marrow 265 635
Small intestinesa 8047 8052
Lower large intestinesa 8107 8232
Upper large intestinesa 8063 8099
Stomacha 8045 8047
Liver 420 872
Soft tissues 8045
Testes 39 685
‘Effective’ whole body (see text) 219 099 355 369
aThe major contribution to the dose to these organs is composed of the
estimated ‘soft tissues’ dose. bDifferent organ doses assessed according to
the assumed solubility class (‘W’ or ‘Y’) of plutonium compounds to which
there was exposure (see text).1290 RZ Omar et al
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cancer registrations were restricted to those workers known to be
alive on 1 January 1971 or who joined the work force after that
date. Within the study population, a comparison was made, by
year, of the proportion of deaths from cancer for which a cancer
had also been registered in the national scheme. This showed a
similar pattern to that reported previously (Douglas et al, 1994),
with a decline in the percentages of cancer deaths with previous
cancer registrations from 1987 onwards. We have restricted
analysis of cancer registrations to the period from 1971 to 1986
(inclusive). Of the 13 206 workers eligible for inclusion in
analyses of cancer incidence, 664 were registered with a cancer
(other than of the skin, which site was excluded from analyses
because of the known poor registration of such cancers).
Comparative death and cancer incidence rates
Age, sex and cause-specific death rates for the population of
England and Wales were obtained from the Office for National
Statistics (ONS) for each of the years 1950—92 (in 5-year age
groups up to the age of 85 years and for 85 years and older).
Cancer registration rates were obtained for both England and
Wales (1971—86) and for the Northern Region (1971—84).
Professor M Gardner and Dr P Winter had previously provided us
with mortality rates from selected causes for Cumberland for
1968—78 (Gardner et al, 1983, 1984) which we used to estimate
death rates up to 1978. Data for the period 1980—92 from ONS
were used to estimate Cumbrian death rates from 1979 to 1992.
Cumbria is the county in which the Sellafield plant is located and it
overlaps substantially with the old county of Cumberland which
existed before boundary and name changes in 1974.
Radiation doses
External radiation
The methods used to assess and validate external exposure to
radiation have been given previously (Smith and Douglas, 1986).
Briefly, records of radiation doses, estimated from film badge
dosimeters worn on the trunk, have been kept by BNFL for all
workers who, other than infrequently, entered areas where it was
possible they would be exposed to radiation (￿controlled areas￿).
The 10 382 workers for whom such records were kept, or who had
been monitored for internal radiation exposure (see below), have
been designated ￿radiation workers￿ and all other workers as ￿non-
radiation workers￿. For each radiation worker, BNFL supplied us
with an annual dose of whole-body penetrating radiation (in mSv),
for each of the years 1947—90 (Douglas et al, 1994).
Plutonium exposure
There are two types of plutonium exposure recorded at Sellafield.
These are ￿plutonium alpha￿ radioisotopes of plutonium (mostly
239Pu but some 240Pu and 238Pu) that decay via the emission of alpha
particles, and 241Pu which decays by beta particle emission to the
alpha emitter americium 241. A proportion of the plutonium which
enters into the body after exposure is excreted in urine and the
amount excreted can be used to estimate the quantity of plutonium
retained in the body. This is expressed as activity taken in and
retained per year and is termed the plutonium uptake.
Riddell et al (1998) detail the methods used by BNFL to assess
the radiation doses acquired by workers at the Sellafield plant
through exposure to plutonium. A summary of the approach
adopted is given below.
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Figure 1 Numbers of plutonium workers employed by year and average
annual uptakes of 241Pu and plutonium alpha among workers for whom
assessments were made. °, average plutonium alpha, +, average 241Pu;
–, no. of plutonium workers
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Figure 2 Cumulative estimated uptakes of (A) plutonium alpha and (B)
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Assessment of plutonium uptake by Sellafield workers has been
made, principally, through monitoring urine samples. Urine
samples have been collected on a regular basis for persons
working in areas of the plant where such exposure might occur.
We have classified the 5203* workers who were ever monitored
for plutonium exposure as ￿plutonium workers￿ (irrespective of
whether or not plutonium was ever detected in a urine sample). For
43 of these workers, we were not supplied with a film badge
record, but for purposes of analysis they have been classified as
radiation workers. The frequency of urine collections and the
methods for assessing the samples have changed over time, as
more sensitive detection methods were developed.
Britcher et al (1994) have summarized plutonium monitoring
procedures at Sellafield at different times. The first records of
urine monitoring for plutonium exposure in the plant date from
1951. This was shortly after the start of reprocessing operations,
when a pilot monitoring programme was instituted. By 1952, a
routine monitoring scheme was operating for persons working in
areas where plutonium exposure was possible. Urine samples were
collected from workers in those areas at 3- or 6-month intervals.
Additional samples were collected if an excretion rate of 46 mBq
or more was measured in a sample. The volume of urine that was
required to be collected was only 100 ml. In 1961, the frequency
of urine sampling was increased to monthly for those working full-
time in areas where exposure was possible, and bimonthly for
those who worked for only some of the time in such areas.
Additional urine samples were collected from workers with
abnormal routine samples [e.g. those with activity not consistent
with a previous result or with the general level (A Riddell,
personal communication)]. In 1968, the urine sampling procedure
was modified to collect five 1 l samples at six-month intervals. An
additional three 1 l samples were collected after potential acute
exposure events. Since 1980, four 1 l samples have been collected
at 6-month intervals for routine monitoring of workers. The assay
methods have improved over time. Before 1961, the minimum
detectable plutonium level in a urine sample was 4.6 mBq [though
levels were generally reported only as ￿less than 46 mBq￿, which
was a local control limit that was applied in the plant, with higher
values leading to specific investigations (Dr R Strong, personal
communication)]. In 1961, this reduced to 2.3 mBq and in 1986 to
0.5 mBq (Britcher et al, 1994).
Assessment of plutonium uptake
Two methods have been used by BNFL for assessing the uptake of
plutonium alpha by individual workers. Individual assessments of
uptake (￿special assessments￿) were made for 993 workers for a
variety of reasons, including those known to have been involved in
an exposure ￿incident￿ or who had claimed compensation for cancers
potentially caused by radiation exposures incurred at the plant. These
assessments involved a detailed consideration by a health physicist of
likely exposures, based on full work history records and the circum-
stances of known acute exposure incidents as well as on the urine
assays. ￿Standardized￿ assessments were made for 3616 workers by
assuming that exposure to plutonium started 6 months before the date
on which the first urine sample was collected for a worker and ended
at the date of the last urine sample. For purposes of estimation,
uptake was assumed to be at a constant rate between these dates.
Annual uptakes of plutonium alpha were estimated from the assays
on urine samples based on a mathematical function, which was
derived assuming decay according to an exponential function in the
amounts excreted in urine with time since exposure (Jones, 1985).
A study conducted in the late 1960s revealed substantial adventi-
tious contamination of urine samples. This led to changes in
sampling arrangements, which were in place by 1971 (Britcher et
al, 1994). Therefore, for workers for whom urine samples had been
collected in 1971 or later, only the post 1970 samples were used for
the estimation of uptake (including for the period before 1971 by
extrapolation) and results from earlier urine samples were ignored.
Such assessments were possible for 1629 (45%) of the 3616
workers having standardized assessments of uptake. Uptakes for
the other 1987 workers for whom standardized assessments were
made were based on the pre-1971 data. For 725 of the workers who
had provided a urine sample after 1960, of whom 579 had provided
at least one sample after 1970, no sample had given results above
the minimum level of plutonium that could be detected. An upper
limit uptake assessment was generated for these workers by setting
the last sample result equal to the relevant limit of detection.
No assessments were made for 585 workers who had only
provided urine samples before 1961, and all of which were
recorded as less than 46 mBq. In addition, uptake assessments
were not available for nine plutonium workers who had no usable
urine data. These 594 workers were known to have been poten-
tially exposed to plutonium, however, and are classified as pluto-
nium workers in our analyses.
Radiochemical analysis of urine samples was not carried out for
the assessment of 241Pu and, hence, ingrown americium-241.
*The number of plutonium workers (5203) is slightly smaller than that given in
Riddell et al (1998) (5250) as for some workers there were inconsistencies in the
data, in particular the dates of monitoring for plutonium fell outside their recorded
employment period.
Table 3 Standardized mortality ratios (SMRs) for all causes of death and all cancers among plutonium workers, other radiation workers and all workers,
comparing rates with those for England and Wales (E&W) and Cumbria
All cancers Causes other than cancer All causes
Group of No. of SMR SMR No. of SMR SMR No. of SMR SMR
workers deaths E&W Cumbria deaths E&W Cumbria deaths E&W Cumbria
Radiation 738 96 97 1944 97 89*** 2682 97* 91***
Plutonium 384 100 101 961 97 90*** 1345 98 92**
Other radiation 354 92 93 983 97 89*** 1337 96 90***
Non-radiation 299 93 96 873 102 94* 1172 100 94*
All 1037 95* 97 2817 99 91** 3854 98 92***
*P < 0.05; **P < 0.01; ***P < 0.001.1292 RZ Omar et al
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Uptake of 241Pu was inferred from the assessed plutonium alpha
uptake by the application of a factor relating 241Pu to plutonium
alpha in plant material on a yearly basis depending upon the
average recorded burn-up of the fuel reprocessed in each year
(Riddell and Britcher, 1994). The Sellafield plant was mostly
engaged in military production before 1961 and there was very
little exposure to 241Pu during this period.
It has not been possible to validate satisfactorily estimates of
plutonium uptake based upon the measurement of plutonium alpha
excreted in urine, derived using the Jones model (Jones, 1985).
However, assessments of plutonium burden in the small number of
workers who had a detailed autopsy have indicated that the Jones
model, on average, overestimates the body burden by around a
factor of three (Lawson et al, 1989; Riddell et al, 1998). The esti-
mates of doses based on uptake of plutonium based on the Jones
model had been reduced by a factor of three to allow for this over-
estimation, before they were provided to us by BNFL.
Organ doses
The doses to each organ in each year were calculated by BNFL
using dosimetric models based on the distribution of plutonium
activity between organs and its clearance using standard metabolic
models recommended by the International Commission on
Radiological Protection (ICRP, 1986). These models relate to a
reference 70-kg male worker and, thus, only approximate the
deposition, distribution and retention of radionuclides in any given
individual. Estimates of organ-specific doses (in mSv) were made
for small intestines, upper and lower large intestines, stomach,
lung, soft tissues, liver, testes, bone and red bone marrow. Doses
inferred from urine samples as having been received in the lung,
stomach, upper and lower large intestines and small intestines
depend on the chemical solubility of the plutonium. The plutonium
present at Sellafield has been classified as ￿W￿ or ￿Y￿ (weeks or
years), which refer to its retention time in the lungs, depending on
the solubility class of the plutonium. This classification applies to
Table 4 Observed and expected numbers of deaths from cancers of specific sites among plutonium, other radiation and non-radiation workers and rate ratios
comparing radiation workers with non-radiation workers and plutonium workers to other radiation workers
Cancer site Plutonium workers Other radiation Rate ratio Non-radiation Rate ratio All workers
workers workers (ICD code – eighth revision)
Obs Exp SMR Obs Exp SMR
(plutonium vs.
Obs Exp SMR
(rad. vs
Obs Exp SMR SMR
E&W E&W E&W E&W
other rad.)
E&W E&W
non-rad)
E&W E&W Cumbria
Lip (140) 0 0.14 0 1 0.15 680 0.00 0 0.12 0 ∞ 1 0.40 247
Tongue (141) 1 1.29 77 2 1.28 156 0.47 0 0.94 0 ∞ 3 3.52 85
Mouth and pharynx (143–149) 0 3.97 0 3 3.91 77 0.00 3 2.88 104 0.24 6 10.76 56*
Oesophagus (150) 16 13.35 120 14 12.74 110 0.96 8 9.05 88 1.92 38 35.15 108 104
Stomach (151) 33 34.43 96 45 34.71 130 0.72 32 27.48 116 0.93 110 96.66 114 103
Small intestines (152) 2 0.76 263 0 0.77 0 ∞ 0 0.62 0 ∞ 2 2.15 93
Colon (153) 25 24.52 102 27 24.64 110 0.89 20 22.68 88 0.92 72 71.86 100 92
Rectum (154) 17 16.91 101 15 16.83 89 1.11 20 13.70 146 0.62 52 47.45 110 111
Liver and gall bladder 1 5.17 19** 1 5.08 20** 0.85 2 4.14 48 0.34 4 14.40 28***
(155–156)
Pancreas (157) 17 16.32 104 15 16.07 93 1.00 12 12.92 93 1.13 44 45.32 97 88
Larynx (161) 3 3.65 82 0 3.55 0 ∞ 2 2.34 86 0.74 5 9.54 52*
Lung (162) 133 145.78 91 113 141.09 80** 1.12 92 94.37 97 0.98 338 381.35 89* 96
Pleura (163.0) 8 1.70 471*** 6 1.54 390* 1.15 0 0.76 0 ∞ * 14 3.99 351***
Bone (170) 0 1.10 0 1 1.23 81 0.00 1 1.02 98 1.12 2 3.34 60
Connective tissue (171) 0 1.31 0 3 1.33 226 0.00 0 1.02 0 ∞ 3 3.66 82
Melanoma (172) 1 2.74 36 4 2.84 141 0.24 3 2.28 131 0.65 8 7.87 102
Breast (174) 6 2.55 236* 2 5.92 34* 7.66** 21 28.35 74 1.35 29 36.83 79 97
Uterus (180–182) 0 0.55 0 2 1.48 135 0.00 9 8.28 109 1.46 11 10.32 107 111
Ovary (183) 1 0.63 158 1 1.65 60 2.18 7 8.93 78 1.92 9 11.22 80 88
Other female genital (184) 0 0.04 0 0 0.11 0 – 1 0.74 134 – 1 0.89 112
Prostate (185) 22 21.36 103 22 20.62 107 0.95 7 13.32 53* 2.21* 51 55.30 92 95
Testis (186) 2 1.39 144 2 1.62 123 1.51 1 0.73 138 1.32 5 3.74 134
Other male genital (172.5, 187) 0 0.58 0 0 0.58 0 – 0 0.34 0 – 0 1.50 0
Bladder (188) 17 13.86 123 12 13.58 88 1.25 10 9.93 101 0.88 39 37.37 104 108
Kidney (189) 5 7.28 69 8 7.07 113 0.56 2 4.85 41* 2.71 15 19.21 78 73
Brain and CNS (191–192) 10 10.46 96 8 10.57 76 1.35 6 7.39 81 0.87 24 28.44 84
Thyroid (193) 1 0.67 150 3 0.70 429* 0.28 2 0.79 253 2.45 6 2.16 278*
Ill-defined and secondary 29 20.13 144* 16 19.52 82 1.90* 23 16.13 143 0.96 68 55.78 122
(195–199)
Non-Hodgkin’s lymphoma 12 8.18 147 8 8.13 98 1.39 2 6.00 33* 2.83 22 22.32 99
(200, 202)
Hodgkin’s disease (201) 4 2.95 136 1 3.28 30* 3.71 3 2.28 132 0.54 8 8.50 94
Multiple myeloma (203) 5 4.63 108 3 4.49 67 1.67 3 3.59 84 0.88 11 12.71 87
Leukaemia (204–208) 7 9.86 71 9 10.17 88 0.79 4 8.10 49* 1.27 20 28.14 71* 75
Other neoplasms 6 7.82 77 7 6.79 103 0.92 3 5.38 56 1.86 16 19.06 84
(140–209 excluding above)
All neoplasms 384 385.10 100 354 384.04 92 1.05 299 321.45 93 1.06 10371090.91 95* 97
Person–years at risk 134 817.2 154 552.5 126 061.9 415 431.6
*P < 0.05; **P < 0.01; ***P < 0.001.Cancer risks among plutonium workers 1293
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a range of half times (ICRP, 1986). The actual solubility class was
not known for each plutonium worker and most may have been
exposed to a mixture of the two solubility classes of plutonium.
We conducted separate analyses of doses for these organs
assuming lung clearance rates of either weeks or years. However,
we present analyses based on the Y class because measurements
made on the solubility of plutonium compounds commonly found
at Sellafield show that the majority exhibit behaviour closest to
class Y (Riddell et al, 1998). Plutonium alpha and 241Pu were
combined for the assessment of organ-specific doses. Table 2
shows the collective whole-body doses accumulated up to 1990
from external radiation for all radiation workers and for plutonium
workers, and also shows the estimated organ-specific and ￿effec-
tive￿ whole-body doses from plutonium exposure for those
workers for whom such an assessment was made.
Figure 1 shows the number of plutonium workers by year from
1951, when plutonium exposure monitoring was started at the
plant, until 1990. The numbers rose up until 1962 to about 2300
workers and, thereafter, stayed between about 1900 and 2300
workers per year up to 1979. Note that the decline in more recent
years arises, at least in part, because we have only included workers
in the study who were first employed before 1976. Also shown in
Figure 1 are the estimated average annual uptakes of 241Pu and
plutonium alpha for the workers for whom such assessments were
Table 5 Observed and expected numbers of deaths from causes other than cancers among plutonium, other radiation and non-radiation workers and rate
ratios comparing radiation workers with non-radiation workers and plutonium workers with other radiation workers
Cause of death Plutonium workers Other radiation Rate ratio Non-radiation Rate ratio All workers
workers workers (ICD code – eighth revision)
Obs Exp SMR Obs Exp SMR
(plutonium vs.
Obs Exp SMR
(rad. vs
Obs Exp SMR SMR
E&W E&W E&W E&W
other rad.)
E&W E&W
non-rad)
E&W E&W Cumbria
Infectious and parasitic 5 10.75 47* 8 12.20 66 0.63 11 13.07 84 0.63 24 36.07 67* 102
(001–136)
Tuberculosis (100–199) 0 6.54 0 2 7.60 26** 0.00 9 8.77 103 0.18* 11 22.94 48** 59*
Benign and unspecified neoplasms 2 4.00 49 5 4.04 118 0.38 4 3.92 102 0.37 11 12.21 90
(210–239)
Endocrine, nutrition and metabolic 13 15.32 85 10 15.56 64 1.42 12 14.46 83 0.72 35 45.35 77
disorders and immunity
disorders (240–279)
Diabetes (250) 10 11.82 85 8 11.90 67 1.24 9 10.88 83 0.70 27 34.61 78 72*
Diseases of blood and  1 2.23 45 3 2.44 123 0.34 4 2.76 145 0.43 8 7.43 108
blood-forming organs (280–289)
Aplastic anaemia (284) 0 0.54 0 1 0.57 175 0.00 2 0.55 366 0.60 3 1.65 181
Other anaemias (280–283, 285) 1 0.96 104 1 1.11 90 0.90 1 1.51 66 0.64 3 3.58 84
Other blood disorders (286–289) 0 0.74 0 1 0.78 128 0.00 1 0.71 140 0.17 2 2.23 90
Mental disorders (290–315) 10 7.23 138 7 7.73 91 1.37 11 8.55 129 0.63 28 23.51 119
Diseases of the nervous and  11 19.25 57* 18 20.09 90 0.59 11 17.59 63* 1.18 40 56.95 70**
sense organs (320–389)
Epilepsy (345) 0 2.47 0 0 2.81 0 – 0 2.08 0 – 0 5.28 0
Multiple sclerosis (340) 2 2.77 72 5 2.96 169 0.36 0 2.94 0 ∞ 7 8.68 81
Disease of circulatory system 723 656.90 110** 690 658.70 105 1.05 576 542.18 106 1.01 19891858.19 107** 94**
(390–458)
Ischaemic heart disease 498 451.47 110* 485 442.96 109* 1.01 371 322.98 115** 0.96 13541217.67 111*** 97
(410–414)
Cerebrovascular diseases  137 108.21 127** 117 114.11 103 1.27* 111 119.51 93 1.28* 365 341.91 107 89*
(430–438)
Diseases of respiratory system 99 142.33 70*** 111 150.24 74*** 0.88 121 138.23 88 0.78* 331 430.93 77*** 82***
(460–519)
Influenza (470–474) 4 2.83 141 4 3.39 118 1.07 3 3.78 79 1.38 11 10.01 110 98
Pneumonia (480–486) 26 44.22 59** 46 48.89 94 0.61* 45 54.26 83 0.75 117 147.41 79** 96
Bronchitis (460–466, 490–493) 42 59.01 71** 42 62.47 67** 0.93 45 52.64 85 0.78 129 174.18 74*** 74***
Diseases of digestive system 23 36.79 63** 40 38.10 105 0.60* 26 34.16 76 1.36 89 109.09 82*
(520–577)
Peptic ulcer (531–534) 10 10.84 92 10 11.36 88 1.07 4 10.03 40 1.85 24 32.25 74 68*
Cirrhosis (571) 3 8.68 35** 8 8.58 93 0.34 4 6.13 65 0.75 15 23.40 64 64*
Diseases of genitourinary system 18 15.32 117 14 16.84 83 1.33 13 17.15 76 1.12 45 49.33 91
(580–629)
Prostatic hyperplasia (600) 6 2.06 291* 2 2.37 84 2.72 2 2.36 85 1.52 100 6.79 147 130
Diseases of pregnancy 0 0.06 0 0 0.16 0 – 3 0.82 368 0.00 3 1.04 288
(630–678)
Symptoms, signs and ill-defined 1 1.76 57 4 2.04 196 0.27 8 2.67 299* 0.20* 13 6.47 201*
conditions (780–796)
Accidents and violence (800–999) 51 67.12 76* 64 75.25 85 0.89 66 50.70 130* 0.60** 181 193.21 94 91
All causes other than cancer 961 987.24 97 983 1012.44 97 0.98 873 856.00 102 0.92 28172856.67 99 91
*P < 0.05; **P < 0.01; ***P < 0.001.1294 RZ Omar et al
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made (see above). Uptake of plutonium alpha was greatest in the
early years of the plant￿s operation and declined markedly there-
after. Estimated uptake of 241Pu rose from 1960 to a maximum
around 1971 and has declined since then. Figure 2 shows the distri-
butions of estimated total uptakes of plutonium alpha and 241Pu
among the plutonium workers for whom uptakes were assessed.
We derived an estimate of the ￿effective￿ whole-body plutonium
dose (mSv) from the organ-specific doses supplied by BNFL. This
was used to assess mortality in relation to plutonium exposure for
all cancers. The estimate of the effective whole-body dose was
based on the method detailed in ICRP 30 (ICRP, 1979) and calcu-
lated as the weighted sum of organ-specific doses. The weighting
factor for a particular organ represents the contribution of that
organ to the total stochastic risk (for both fatal malignant and
hereditary disease) due to the uniform irradiation of the whole
body. Using the ICRP 30 model, the weighting factor for gonads is
large (25%), because of the genetic risk, and was considered to be
inappropriate for the purposes of this study. Thus, in estimating
effective whole-body dose for these analyses, we used revised
weighting factors derived by excluding gonads and scaling up the
weights associated with the other organs proportionately. The
weights applied were thus: bone marrow 0.16; bone surface 0.04;
lung 0.16; breast (soft tissue) 0.20; thyroid (soft tissue) 0.04;
stomach 0.08; small intestines 0.08; upper large intestines 0.08;
lower large intestine 0.08; and liver 0.08. Effective whole-body
doses were calculated assuming both weekly and yearly lung
clearance rates.
Statistical analyses
The mortality rates of workers in Sellafield were compared with
those of the population of England and Wales and also with the
rates for Cumbria. Cancer incidence rates were compared with
those of England and Wales and of the Northern UK region. The
expected number of deaths or cancer registrations for each cause
were estimated by multiplying the number of person—years at risk
during the study period by the appropriate national, Northern UK
or Cumbrian rates. Each worker contributed person—years at risk
Table 6 Deaths from selected cancers among radiation workers by cumulative external radiation dose (adjusted for age, sex and calendar period). Figures in
parentheses are expected distribution of deaths assuming no relation between dose and cancer risk. Data in the body of the table are for analyses including no
lag period
Cancer site Total z-statistica by lag of
(ICD code – eighth deaths radiation dose
revision) External radiation dose monitored (mSv) (years)
<10 10–19 20–49 50–99 100–199 200–399 400+ 0 10 20
Oesophagus (150) 3 (4.0) 0 (2.6) 5 (5.7) 9 (4.7) 1 (4.6) 7 (4.5) 5 (3.9) 30 1.04 0.82 0.32
Stomach (151) 14 (12.6) 8 (6.9) 14 (14.2) 12 (12.8) 8 (11.9) 11 (10.8) 11 (8.8) 78 0.48 0.22 –0.51
Colon (153) 11 (8.4) 6 (4.4) 5 (9.3) 10 (8.3) 8 (7.8) 8 (7.5) 4 (6.3) 52 –0.91 –0.48 –0.73
Rectum (154) 4 (5.7) 2 (2.5) 5 (5.4) 4 (4.9) 6 (4.9) 6 (4.5) 5 (4.1) 32 0.99 1.27 0.98
Pancreas (157) 5 (4.4) 4 (3.0) 4 (5.8) 6 (4.5) 3 (4.8) 4 (5.0) 6 (4.5) 32 0.38 0.56 1.57
Lung (162) 39 (39.2) 19 (21.5) 51 (44.0) 38 (37.4) 36 (36.3) 42 (37.0) 21 (30.4) 246 –1.43 –0.78 –1.27
Pleura (163.0) 2 (1.8) 1 (1.3) 1 (2.4) 1 (2.0) 3 (2.1) 5 (2.3) 1 (2.1) 14 0.14 0.28 –0.60
Melanoma (172) 0 (1.0) 1 (0.5) 1 (0.9) 1 (0.8) 2 (0.8) 0 (0.7) 0 (0.5) 5 –0.72 –0.60 –0.33
Breast (174) 3 (4.2) 1 (1.4) 1 (1.6) 3 (0.5) 0 (0.3) 0 (0.0) 0 (0.0) 8 1.00 0.73 1.48
Prostate (185) 5 (7.0) 3 (3.6) 9 (7.7) 8 (6.5) 8 (6.2) 8 (6.9) 3 (6.2) 44 –0.98 –0.77 0.02
Bladder (188) 3 (3.8) 5 (2.3) 5 (4.8) 2 (4.2) 4 (4.5) 6 (5.2) 4 (4.4) 29 –0.16 0.31 –0.70
Kidney (189.0) 1 (1.7) 2 (1.1) 1 (2.4) 7 (1.9) 1 (2.0) 1 (2.2) 0 (1.8) 13 –1.76b –1.68b –1.56b
Brain and CNS (191–192) 1 (3.2) 3 (2.0) 5 (3.6) 4 (2.5) 2 (2.6) 2 (2.3) 1 (1.7) 18 –0.62 –0.48 0.15
III-defined and secondary 5 (7.7) 6 (4.4) 7 (8.6) 4 (6.7) 9 (6.2) 8 (6.2) 6 (5.2) 45 0.94 1.72* 1.34
(195–199)
Non-Hodgkin’s lymphoma 5 (2.8) 2 (1.9) 3 (3.5) 1 (3.0) 5 (3.1) 1 (3.0) 3 (2.7) 20 –0.30 –0.04 0.74
(200, 202)
Hodgkin’s disease (201) 1 (0.8) 1 (0.6) 1 (1.0) 0 (0.9) 2 (0.7) 0 (0.6) 0 (0.4) 5 –0.80 –0.37 0.49
Multiple myeloma (203) 0 (1.3) 0 (0.8) 2 (1.5) 3 (1.2) 1 (1.1) 0 (1.1) 2 (1.0) 8 0.80 1.44 2.53b
Leukaemia (204–208) 4 (2.8) 1 (1.7) 1 (3.1) 2 (2.5) 2 (2.4) 2 (2.0) 4 (1.5) 16 2.03b 0.44 0.64
2 year lag = 1.73b
Leukaemia (excluding 2 (2.3) 1 (1.3) 1 (2.5) 1 (2.0) 2 (2.1) 2 (1.6) 4 (1.2) 13 2.77b 1.00 1.36
chronic lymphatic) (204.0, 2 year lag = 2.43b
204.2–208.9)
All lymphatic and 10 (7.8) 4 (5.1) 7 (9.3) 7 (7.7) 10 (7.5) 3 (6.9) 9 (5.7) 50 0.88 0.63 1.94*
haematopoietic (200–209)
All neoplasms (140–209) 117 71 130 119 106 116 79 738 –0.76 0.07 –0.10
(121.7) (66.3) (134.1) (111.1) (107.7) (107.4) (89.7)
All causes of death 464 248 470 417 375 413 295 2682 –0.20 1.37 2.42**
(447.6) (242.3) (497.7) (414.2) (391.2) (380.6) (308.4)
Person–years at risk 67 518 35 473 59 731 42 901 38 275 28 808 16 664 289 370
aAbsolute values of the z-statistic corresponding (approximately) to P-values 0.05, 0.01 and 0.001 are 1.64, 2.33 and 3.09 respectively. bP-values computed by
simulation: kidney (0-year lag = 0.027; 10-year lag = 0.030; 20-year lag = 0.039), myeloma (20-year lag = 0.017), leukaemia (0-year lag = 0.027; 2-year lag =
0.050), leukaemia excluding CLL (0-year lag = 0.006; 2-year lag = 0.015). *P < 0.05; **P < 0.01.Cancer risks among plutonium workers 1295
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from the date of first employment at Sellafield, or from 1 January
1947 for three workers with earlier employment dates, through to
the earliest of 31 December 1992, the date of emigration, death or
when last traced alive. For the analysis of cancer incidence,
workers contributed person—years from the latest of their date of
first employment or 1 January 1971 to the earliest of 31 December
1986 or the date of emigration, death or when last traced alive.
Mortality and cancer incidence were also compared between radi-
ation workers and non-radiation workers and between workers
monitored for plutonium exposure and other radiation workers.
For these comparisons, we used maximum likelihood estimates of
rate ratios and likelihood ratio tests based on Poisson models.
The risk of cause-specific mortality was investigated in relation to
cumulative external radiation exposure and cumulative plutonium
doses. These were analysed by comparing death rates among
workers who had accumulated different levels of exposure and
performing a test for trend to assess the statistical significance of any
association. In general, for the trend tests, we used the dose cate-
gories used in previous analyses (Douglas et al, 1994) (as shown in
Table 6). However, the plutonium doses to organs other than the
lungs, bone surfaces, liver and red bone marrow were relatively low
(Table 2) and for analyses of cancers of these organs, for plutonium
dose alone, we used the dose categories <2, 2—7.9 and ‡ 8 mSv for
trend tests. The risks of cancer of the testes, bone, liver and small
intestines in relation to the relevant organ-specific plutonium doses
were not assessed because of the small number of deaths observed
from these causes. Similar dose—response analyses were conducted
for cancer registrations. The trend analyses for radiation doses from
plutonium were based on 4609 workers who had uptake assessments.
Nearly all of the plutonium workers also had external radiation
recorded. Analyses combining plutonium doses and external doses
were conducted by adding organ-specific or whole-body pluto-
nium doses to the whole-body external radiation dose.
To allow for any delayed effect of radiation exposure, trend
analyses were lagged by 0, 2, 10 and 20 years for leukaemia and
by 0, 10, 20 years for all other cancers. All analyses were adjusted
by age, sex, calendar period and industrial status (Smith and
Douglas, 1986) through stratification.
One-sided statistical significance tests were used because our
prior hypothesis was that workers who had been exposed to higher
levels of radiation would be expected to show increased cancer
death and registration rates. For consistency, unless otherwise
stated, all significance tests presented are one-sided in the direc-
tion of the observed difference or trend. If the number of deaths or
cancer registrations was less than 20, the statistical significance for
a rate ratio and trend statistic was checked by simulation.
RESULTS
Mortality
Table 3 shows standardized mortality ratios (SMRs) for plutonium
workers, all radiation workers and all workers, based on compar-
ison with the mortality rates of the general population of England
and Wales and of Cumbria, for all causes of death and all cancers.
In general, and as found in previous analyses (Smith and Douglas,
1986; Douglas et al, 1994), the overall mortality rate and the
cancer mortality rate of the Sellafield workers were close to those
of the general population of England and Wales (SMRs 98 and 95
respectively). Mortality rates from cancer for all radiation workers
were 4% less than those for England and Wales, and those for
plutonium workers were very close to those for England and Wales
Table 7 Deaths from selected cancers among plutonium workers by cumulative organ-specific plutonium dose plus external radiation dose, assuming yearly
(Y) clearance (adjusted for age, sex and calendar period). Figures in parentheses are expected distribution of deaths assuming no relation between dose and
cancer risk. Data in the body of the table are for analyses including no lag period
Cancer site Total Z-statistica by lag of
(ICD code – 8th revision) Plutonium dose plus external dose (mSv) deaths radiation dose (years)
< 10 10–19 20–49 50–99 100–199 200–399 400+ 0 10 20
Stomach (151) 1 (1.0) 1 (0.8) 4 (2.9) 2 (4.0) 4 (5.6) 6 (5.8) 8 (6.0) 26 0.92 0.78 0.13
Colonb (153) 1 (0.9) 0 (0.5) 2 (2.1) 3 (2.3) 5 (3.4) 3 (3.5) 2 (3.4) 16 –0.85 –0.48 0.14
Pancreasc (157) 0 (0.4) 1 (0.5) 1 (2.0) 3 (1.8) 2 (2.9) 4 (4.0) 5 (4.3) 16 0.36 0.17 1.35
Lung (162) 0 (0.7) 1 (1.1) 3 (3.4) 7 (6.0) 10 (12.9) 29 (22.9) 55 (58.0) 105 –0.30 –0.11 –0.59
Pleurac (163) 0 (0.1) 0 (0.2) 0 (0.8) 1 (0.9) 2 (1.3) 3 (1.8) 1 (1.9) 7 –0.21 0.03 –0.86
Breastc (174) 2 (0.4) 0 (0.6) 1 (2.7) 2 (0.9) 0 (0.3) 0 (0.1) 0 (0.0) 5 –0.55 –0.12 0.59
Prostatec (185) 0 (0.4) 0 (0.4) 3 (1.8) 4 (2.2) 3 (3.1) 3 (3.9) 3 (4.3) 16 –1.02 –0.75 –0.62
Bladderc (188) 0 (0.2) 1 (0.2) 1 (1.0) 0 (1.4) 2 (1.9) 3 (2.6) 3 (2.6) 10 0.41 0.88 –0.73
Brain and CNSc (191–192) 0 (0.4) 0 (0.4) 1 (1.2) 3 (1.2) 1 (1.6) 1 (1.8) 2 (1.3) 8 0.39 0.12 1.16
Ill-defined and secondaryc 2 (1.2) 1 (0.8) 0 (2.9) 2 (2.8) 6 (4.1) 6 (4.4) 4 (4.8) 21 0.11 0.47 –0.12
(195–199)
Non-Hodgkin’s lymphomac 2 (0.3) 0 (0.4) 2 (1.4) 1 (1.5) 2 (2.1) 2 (2.6) 2 (2.6) 11 –0.82 –0.49 –0.12
(200, 202)
Leukaemiad (204–208) 0 (0.1) 0 (0.2) 0 (0.6) 1 (0.8) 1 (1.5) 2 (1.8) 3 (2.0) 7 1.11 –0.07 0.30
2-year lag 1.25
Leukaemiad (excluding chronic 0 (0.1) 0 (0.2) 0 (0.4) 1 (0.6) 0 (1.2) 2 (1.6) 3 (1.8) 6 1.31 –0.02 0.37
lymphatic) (204.0, 202.2–208.9) 2-year lag 1.44
All malignant neoplasmse 6 (5.3) 9 (4.4) 16 (19.2) 25 (28.2) 55 (53.5) 103 (85.4) 86 (104.0) 300 –1.72* –1.33 –1.02
aAbsolute values of the z-statistic corresponding (approximately) to P-values 0.05, 0.01 and 0.001 are 1.64, 2.33 and 3.09 respectively. bTrend calculated using
lower large intestine dose. cTrend calculated using soft tissue dose. dTrend calculated using red bone marrow dose. eTrend calculated using estimated ‘effective’
whole body dose (see text). *P < 0.051296 RZ Omar et al
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(SMR = 100). The findings with respect to cancer were little
changed if comparison was made with mortality rates for Cumbria,
rather than mortality rates for England and Wales. However,
whereas the mortality rates of Sellafield workers from all causes
other than cancer were similar to those of England and Wales, they
were significantly lower than those of the population of Cumbria.
SMRs for all workers (based on mortality rates for England and
Wales) for all causes of death and all cancers were examined
according to sex, industrial status, calendar period, age at death, time
since first employment and duration of employment at the plant.
Results were broadly similar to those reported previously (Smith
and Douglas, 1986; Douglas et al, 1994) and are not described here.
Table 4 shows SMRs for all workers, plutonium workers and
other radiation workers for specific cancer sites. Also shown are
rate ratios comparing mortality among plutonium workers with
other radiation workers, and comparing radiation workers to non-
radiation workers.
Comparing death rates in the total work force with those of the
population of England and Wales, there were significant excesses
of deaths from cancers of the pleura (14 observed vs. 4.0 expected, 
< 0.001) and thyroid (6 vs. 2.2, P = 0.02) and significant deficits of
deaths from cancers of the mouth and pharynx (6 vs. 10.8, P = 0.04),
liver and gallbladder (4 vs 14.4, P < 0.001), larynx (5 vs. 9.5, P =
0.04), lung (338 vs. 381.3, P = 0.01) and leukaemia (20 vs. 28.1, P =
0.04). Cumbrian rates were available for lung cancer and leukaemia
and the deficits of deaths from these cancers were not significant
when compared with these rates. The excesses of deaths from
cancers of the pleura and thyroid were found in our previous
analysis (Douglas et al, 1994). Since that time, there have been five
additional deaths from pleural cancer (two in 1989, one in 1991 and
two in 1992), but none from thyroid cancer. All 14 deaths from
pleural cancer occurred among radiation workers, but the number
expected among non-radiation workers was small (0.8). The differ-
ence in risk between radiation and non-radiation workers was
just significant (P = 0.05). The increased risk was of similar magni-
tude among plutonium workers and other radiation workers. The
previously reported excess of cancers of ill-defined and secondary
sites (Smith and Douglas, 1986) was now no longer statistically
Table 8 Observed and expected numbers of cancer registrations from cancer-specific sites among plutonium and other radiation workers and rate ratios
comparing plutonium workers with other radiation workers
Cancer site Plutonium workers Other radiation workers Rate ratio
(ICD code – eighth revision)
Obs Exp SRR Obs Exp SRR
(Plutonium vs
E&W E&W E&W E&W
other rad.)
Lip (140) 2 0.88 227 0 0.79 0 ∞
Tongue (141) 2 1.20 166 3 1.08 278 0.55
Mouth and pharynx (143–149) 0 3.86 0 3 3.47 87 0.00
Oesophagus (150) 11 6.84 161 11 6.17 178 0.86
Stomach (151) 17 20.95 81 17 19.03 89 0.82
Small intestines (152) 2 0.60 334 0 0.54 0 ∞
Colon (153) 19 18.59 102 20 17.37 115 0.84
Rectum (154) 18 15.62 115 14 14.26 98 1.23
Liver and gall bladder (155–156) 0 3.13 0 0 2.87 0 –
Pancreas (157) 11 8.85 124 6 8.08 74 1.43
Larynx (161) 3 5.26 57 3 4.60 65 0.92
Lung (162) 81 85.53 95 59 76.01 78* 1.18
Pleura (163.0) 1 1.15 87 3 1.00 299 0.26
Bone (170) 0 0.66 0 1 0.60 166 0.00
Connective tissue (171) 2 1.47 136 4 1.37 292 0.46
Melanoma (172) 1 2.96 34 4 2.95 136 0.29
Breast (174) 4 3.32 121 4 6.84 58 3.81
Uterus (180–182) 0 1.00 0 2 2.34 86 0.00
Ovary (183) 1 0.50 200 2 1.16 172 1.46
Other female genital (184) 0 0.04 0 0 0.10 0 –
Prostate (185) 16 18.36 87 15 17.01 88 1.00
Testis (186) 1 2.91 34 4 2.69 149 0.21
Other male genital (172.5, 187) 0 0.98 0 0 0.87 0 –
Bladder (188) 16 19.27 83 13 17.32 75 1.07
Kidney (189) 3 5.39 56 3 4.83 62 0.93
Brain and CNS (191–192) 6 6.11 98 4 5.54 72 1.35
Thyroid (193) 0 0.80 0 3 0.81 371* 0.00
III-defined and secondary (195–199) 17 13.28 128 17 12.20 139 0.90
Non-Hodgkin’s lymphoma (200, 202) 5 6.76 74 2 6.22 32* 2.08
Hodgkin’s disease (201) 6 2.76 217 3 2.57 117 1.65
Multiple myeloma (203) 3 3.18 94 1 2.90 34 3.01
Leukaemia (204–208) 3 7.51 40* 10 6.93 144 0.31*
Leukaemia excluding CLL (204.0, 204.2–208.9) 3 5.20 58 6 4.81 125 0.50
Other neoplasms (140–209 excluding above) 3 6.55 46 4 6.08 66 0.61
All neoplasms (excluding skin) 254 276.3 92 235 256.6 92 0.99
Person–years at risk 69 472.1 66 629.9
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significant. The sites with a deficit of deaths are similar to those
previously reported, but, at that time, the findings for cancers of
the mouth and pharynx and for leukaemia were not statistically
significant.
The only cancer sites for which there was a significant differ-
ence in the rates among radiation and non-radiation workers were
for cancer of the pleura and cancer of the prostate (rate ratio 2.2,
P = 0.05), the latter being due mainly to a deficit of deaths among
non-radiation workers (compared with mortality rates for England
and Wales).
Comparing plutonium workers with other radiation workers, the
overall death rates from cancer were similar (rate ratio 1.05) but
there were significant excesses of deaths among the former group
from cancer of the breast (rate ratio 7.7, P = 0.01) and cancers of
ill-defined and secondary sites (rate ratio 1.9, P = 0.04). For breast
cancer, there was a significant excess among plutonium workers
and a significant deficit among other radiation workers, compared
with the rates for England and Wales.
Mortality from causes other than cancer for the different worker
groups is shown in Table 5. The only causes of death for which
there were significant excesses of deaths among all workers,
compared with mortality rates for England and Wales, were for
diseases of the circulatory system, owing to an excess of deaths
from ischaemic heart disease (1354 vs. 1217.7, P < 0.001), and
deaths from ill-defined conditions (13 vs. 6.5, P = 0.02). The
former excess was not apparent when expected numbers were
based on Cumbrian mortality rates. Compared with the rates for
England and Wales, there were significant deficits of deaths from
infectious and parasitic diseases, tuberculosis, diseases of nervous
and sense organs, diseases of the respiratory system (pneumonia
and bronchitis) and diseases of the digestive system and also of
diabetes, cerebrovascular diseases, peptic ulcer and cirrhosis when
compared with Cumbrian death rates.
The only cause of death for which there was a significant excess
of deaths among radiation workers compared with non-radiation
workers was for cerebrovascular diseases. There were significant
deficits of deaths among radiation workers compared with other
workers from tuberculosis, diseases of the respiratory system, ill-
defined conditions and accidents and violence.
There were significant deficits of deaths due to pneumonia and
to diseases of the digestive system among plutonium workers
compared with other radiation workers and a significant excess of
deaths due to cerebrovascular diseases. For no other cause of death
was there a significant difference in the mortality rates of pluto-
nium workers compared with other radiation workers.
Trends of mortality with cumulative external radiation
dose
The results for trend analyses examining associations between
cumulative radiation dose and the risk of death from cancer are
shown in Table 6. Only those sites for which there were five or
more deaths are included. Significant positive trends were seen for
ill-defined and secondary cancers (with a lag of 10 years, P =
0.04), leukaemia (with no lag, simulated P = 0.03; 2-year lag,
simulated P = 0.05), myeloma (with a lag of 20 years, P = 0.02)
and all lymphatic and haematopoietic cancers (with a lag of
20 years, P = 0.03). Excluding the three deaths from chronic
lymphatic leukaemia strengthened the leukaemia trend (with no
lag, simulated P = 0.006; 2-year lag, simulated P = 0.02). There
was also a significant positive trend for all causes of death with a
lag of 20 years (P = 0.008). This was due mainly to significant
trends for ischaemic heart disease, mental disorders and pneu-
monia (data not shown). There was a significant negative associa-
tion between mortality from cancer of the kidney and cumulative
dose with no lag period (simulated P = 0.03) and lags of 10 years
(simulated P = 0.03) and 20 years (simulated P = 0.04).
Trends with plutonium dose
Table 7 shows analyses for plutonium workers relating the risk of
death from cancers of specific sites to the estimated organ-specific
radiation doses from plutonium exposure and external radiation
exposure combined. The only statistically significant finding was
a negative trend between the risk of death from any cancer and
cumulative radiation dose, assuming no lag period. There was also
a significant negative trend for all cancers combined (with no lag)
assuming plutonium exposure was in the ￿W￿ class (results not
Table 9 Cancer registrations among plutonium workers by cumulative organ-specific plutonium dose plus external radiation dose, assuming yearly (Y)
clearance (adjusted for age, sex and calendar period). Figures in parentheses are expected distribution of cancer registrations assuming no relation between
dose and cancer risk. Data in the body of the table are for analyses including no lag period
Cancer site Total cancer Z-statistica by lag of
(ICD code – 8th revision) Plutonium dose plus external dose (mSv) registrations radiation dose (years)
<10 10–19 20–49 50–99 100–199 200–399 400+ 0 10 20
Stomach (151) 1 (0.6) 1 (0.4) 1 (1.6) 2 (2.0) 3 (3.1) 4 (3.1) 2 (3.2) 14 –0.62 –0.84 –1.58
Colon (153)c 0 (0.6) 0 (0.4) 1 (1.8) 3 (2.1) 2 (2.8) 4 (3.3) 4 (3.1) 14 0.90 1.23 1.20
Pancreasd (157) 0 (0.3) 1 (0.3) 0 (1.2) 3 (1.2) 0 (1.8) 2 (2.7) 4 (2.6) 10 0.74 0.42 0.63
Lung (162) 0 (0.5) 1 (0.8) 3 (2.4) 4 (4.0) 4 (8.5) 17 (15.5) 41 (38.4) 70 0.76 0.69 0.08
Prostated (185) 0 (0.4) 0 (0.3) 1 (1.1) 4 (1.5) 2 (2.3) 2 (2.8) 2 (2.8) 11 –0.78 –0.32 –0.95
Bladderd (188) 0 (0.3) 1 (0.4) 0 (1.2) 0 (1.6) 2 (2.0) 5 (2.9) 3 (2.6) 11 0.96 0.22 –0.99
Brain and CNSd (191–192) 0 (0.3) 0 (0.3) 1 (0.8) 2 (0.7) 0 (1.1) 0 (1.0) 2 (0.8) 5 0.85 –0.20 0.51
Ill-defined and secondaryd 2 (1.3) 0 (0.7) 0 (1.8) 2 (2.0) 6 (2.7) 2 (2.3) 1 (2.2) 13 –0.59 0.07 –0.40
(195–199)
All lymphatic and 1 (1.4) 0 (0.6) 3 (1.5) 1 (1.7) 0 (2.6) 3 (3.4) 7 (3.8) 15 1.95b 1.74b 3.78b
haematopoietice (200–209)
aAbsolute values of the z-statistic corresponding (approximately) to P-values 0.05, 0.01 and 0.001 are 1.64, 2.33 and 3.09 respectively. bP-values computed by
simulation: all lymphatic and haematopoietic neoplasms (0-year lag = 0.024; 10-year lag = 0.046; 20-year lag <0.001). cTrends were calculated using lower
large intestine dose. dTrends were calculated using soft tissue dose. eTrends were calculated using red bone marrow dose.1298 RZ Omar et al
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shown). With the same assumption, there were also significant
negative associations for deaths from lung cancer with 0-, 10- or
20-year lags.
Cancer incidence
The period for which cancer registrations were analysed is the
same as that considered in our previous report (Smith and
Douglas, 1986), though 11 more cancer registrations have been
discovered in the interim and one other which had been classified
as ￿other cancer￿ was changed to stomach cancer. The overall find-
ings for all workers were essentially the same as reported previ-
ously (Douglas et al, 1994) and are not tabulated. The only site for
which there was a significant excess of cancer registrations was for
cancers of ill-defined and secondary sites (53 observed vs 35.5
expected, P = 0.004). There were significant deficits for cancers of
the liver and gallbladder (1 vs 8.3), breast (21 vs 40.1) and all sites
combined (664 vs 750.0). Compared with Northern region rates,
the excess of cancers of ill-defined and secondary sites was not
statistically significant, but there were additional significant
deficits of registrations from cancers of the mouth and pharynx
(5 vs 13.2), stomach (45 vs 62.5), larynx (7 vs 14.3), lung
(192 vs 256.0) and bladder (35 vs 50.0).
Table 8 shows the number of cancer registrations for different
sites among plutonium workers and among other radiation
workers compared with expected numbers based on rates for
England and Wales. The incidence rate of all cancers combined
was similar among plutonium workers and among other radiation
workers (rate ratio = 0.99). Among radiation workers other than
plutonium workers, there were significant deficits of registrations
from cancers of the lung and non-Hodgkin￿s lymphoma and an
excess of registrations for thyroid cancer. However, leukaemia was
the only cancer for which there was a significant difference in
registration rates for the two types of workers, due largely to a
significant deficit of registrations from this cause among pluto-
nium workers compared with rates for England and Wales.
Trends with organ-specific doses
Analyses of trends in cancer incidence in relation to cumulative
external radiation dose among all radiation workers have been
presented previously (for radiation doses lagged by 0 and 10 years
and, in addition, by 2 years for leukaemia) (Douglas et al, 1994).
Only for leukaemia (excluding chronic lymphatic) was there a
significant increase in risk with cumulative dose (for lags of 0 and
2 years). When radiation doses were lagged by 20 years (which
was not done in our previous analyses), there were significant
positive trends with cumulative radiation dose for cancers of the
brain and CNS (simulated P = 0.03), non-Hodgkin￿s lymphoma
(simulated  P = 0.03) and all lymphatic and haematopoietic
neoplasms (P = 0.005).
Table 9 shows trends in cancer incidence among plutonium
workers in relation to cumulative external radiation dose plus the
organ-specific plutonium doses. The only statistically significant
findings were positive trends with cumulative dose, for all lag
periods considered, for all lymphatic and haematopoietic
neoplasms (which were considered together because of the small
numbers of registrations from cancers of the component sites). Of
the seven cancers in the highest exposure group (‡400 mSv), with
zero lag, there were two registrations from each of leukaemia,
myeloma and Hodgkin￿s disease and one from non-Hodgkin￿s
lymphoma. This positive association between cumulative dose and
these sites was also significant when the plutonium dose was
considered alone, due largely to two workers with a cancer of these
sites who had accumulated a plutonium dose (red bone marrow) in
excess of 400 mSv [Hodgkin￿s disease (883 mSv, assuming zero
lag) and myeloma (1102 mSv)]. The only other significant finding
in relation to cumulative plutonium dose and cancers of specific
sites was a positive association for cancer of the pancreas,
assuming a lag of 10 years.
DISCUSSION
Workers at the Sellafield plant had a mortality rate from all causes
of death that was 2% less than that of the general population of
England and Wales and 8% less than the population of Cumbria.
Mortality rates from cancer among workers were 5% and 3% less
than those of these two populations respectively. Cancer mortality
rates among radiation workers were slightly higher than those
among non-radiation workers (rate ratio 1.06), but not signifi-
cantly so (Tables 3 and 4). These findings are similar to those
reported previously, but based on a further 4 years of follow-up
(Douglas et al, 1994). In other studies of workers in nuclear plants,
mortality rates have been reported which were substantially less
than those of the general population. We have discussed previ-
ously the significance of the apparent absence of a large ￿healthy
worker￿ effect among Sellafield workers (Smith and Douglas,
1986; Douglas et al, 1994) and we do not believe that our failure to
find such an effect is because of a deleterious effect of radiation
exposure.
In previous analyses (Douglas et al, 1994), we noted significant
excess risks of cancers of the pleura, thyroid and of ill-defined and
secondary sites among Sellafield workers. The excesses for the first
two sites persist with further follow-up, but that for the last site is
no longer significant (Table 4), though, as previously we found a
significant association between the risk of death from this cause
and accumulated external radiation dose (Table 6). This finding is
consistent with radiation being a cause of these ill-defined and
secondary cancers, but does not account for the excess being
among non-radiation workers. Mortality rates for these cancers
among radiation workers were slightly lower than those among
non-radiation workers (rate ratio 0.96, Table 4). An excess of these
cancers has not been found in studies of other radiation workers and
nor has the association with cumulative radiation dose (Gilbert et
al, 1993; Carpenter et al, 1994; Cardis et al, 1995). Thus, our find-
ings are difficult to interpret for this, by definition, ill-defined group
of tumours. There have been no additional deaths from thyroid
cancer since our last report but a further five deaths from pleural
cancer, bringing the total to 14 against only four expected. The
mortality from thyroid cancer was higher among radiation workers
than among non-radiation workers, but not significantly. All of the
deaths from pleural cancer were among radiation workers, and the
difference compared with non-radiation workers was just statisti-
cally significant (P = 0.05, Table 4). For neither site was there a
significant association between the risk of the cancer and accumu-
lated external radiation dose (Table 6, data for thyroid cancer not
shown). A significant excess of thyroid cancer has not been found
in other studies of nuclear workers (Gilbert et al, 1993; Carpenter et
al, 1994; Cardis et al, 1995), but an excess was reported in a
national study of radiation workers that included workers from
Sellafield (Kendall et al, 1992). We commented at length on the
excess of cancer of the pleura in our previous report and althoughCancer risks among plutonium workers 1299
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the possibility of radiation exposure contributing to this excess
cannot be excluded, it is plausible that the major part of the excess
is due to exposure to asbestos. It is of interest, however, that a
significant excess of deaths from pleural cancer has not been found
in other studies of nuclear workers in the UK (Carpenter et al,
1994). The excess at Sellafield was of similar magnitude among
plutonium workers and among other radiation workers (Table 4).
Leukaemia is the cancer most readily induced by radiation and
is the one for which an excess is most likely to be observed among
radiation workers. Since our last report, there have been five addi-
tional deaths from this cause in the total worker population, which
is about the number expected based on rates for England and
Wales, but overall there was a significant deficit of deaths from
this cause (20 vs 28.1 expected, P < 0.05, Table 4). The deficit was
most marked among non-radiation workers, but was also present
among radiation workers. However, when leukaemia mortality
risk was related to accumulated external radiation dose there was a
significant dose—response relationship, using lag periods of 0 and
2 years, which was strengthened when deaths from chronic
lymphatic leukaemia were excluded (which cause has not been
related to radiation exposure in other studies of radiation-exposed
populations). It seems likely that this is a real effect of radiation
exposure at the plant and the magnitude of the increase in risk with
radiation dose is in line with dose—response estimates that have
been derived in populations exposed to high doses of radiation, as
we have discussed previously (Douglas et al, 1994).
With continued follow-up of the Sellafield population, substan-
tial numbers of workers have now been followed for several
decades. Indeed, the average follow-up time is now 29 years. We
have, therefore, examined the relationship between cancer risk and
accumulated radiation dose, not only lagged by 0 and 10 years
(and 2 years for leukaemia), as in previous analyses (Douglas et al,
1994), but also by 20 years to look for possible effects after long
induction times. With this long lag period, the only cancer site for
which this gave a significant trend of increasing risk with dose was
for myeloma (P = 0.02, Table 6), apart from all lymphatic and
haematopoietic neoplasms which grouping includes myeloma.
This is similar to the finding we reported originally (Smith and
Douglas, 1986), using a 15-year lag period and we have speculated
that this may represent a true radiation effect (Smith and Douglas,
1986). There has been only one additional death from myeloma
among radiation workers since our previous 2 analyses (Smith and
Douglas, 1986; Douglas et al, 1994) and the total deaths from this
cause among all workers and among radiation workers was about
the same as the expected numbers (Table 4).
An unexpected finding was the association between the risk of
death from all causes combined and accumulated radiation dose,
assuming a 20-year lag period. There was no evidence of such an
effect for all cancers combined and the association was due mainly
to correlations between risk and cumulative dose for mental disor-
ders, ischaemic heart disease and pneumonia. Although there was
a significant excess of deaths from ischaemic heart disease in the
total work force, compared with rates for England and Wales, there
was no excess when comparison was made with Cumbrian rates,
and, for each of these three causes, mortality rates among radiation
workers were lower than those among non-radiation workers,
though in no instance significantly so. There is little evidence from
numerous other studies that radiation exposure influences causes
of death other than cancer even in populations that have been
exposed to relatively high doses, so that our findings are perhaps
most likely to be due to chance.
We have not previously examined mortality patterns among
plutonium workers at the Sellafield plant and this group is the
main focus of this paper. Our analyses are subject to a number of
limitations. Plutonium workers were defined as those who had
ever provided a urine sample for plutonium assay. Some of these
workers will never have been exposed to plutonium and, even for
those that were, the exposure may not have been detected because
of the low sensitivity of the assay method used, particularly during
the early years of the plant￿s operation. Of the workers for whom a
plutonium uptake assessment was made, 21.5% had ￿special￿
assessments of their annual uptakes, taking account not only of
urine assays but also knowledge of specific exposure incidents and
place of work within the plant. This group included all of those
who had been involved in specific exposure incidents or who had
been assessed for the nuclear industry compensation scheme. For
the remaining workers, annual uptakes were estimated based on
urine data using only a mathematical model. There are substantial
uncertainties in all these assessments of uptake and few data with
which to validate the estimation methods. This is illustrated by the
fact that uptake levels were divided by three before they were
provided to us by BNFL because of differences between estimates
derived from urine assays and levels measured in the small
number of workers who have had detailed plutonium burdens
measured after death.
As the group of workers for whom special assessments were
made included those claiming a compensation award, we were
concerned that any systematic difference in the plutonium uptakes
estimated by the ￿special￿ and ￿standard￿ methods might lead to
bias. We therefore asked that ￿standardized￿ assessments be made
for the 644 workers who had a special assessment but who were not
known to have had an acute exposure. This comparison showed
that estimates of uptakes from standardized assessments were, on
average, about 25% higher than those obtained using the special
approach. However, there was no evidence that cancer mortality
was higher in those having a special assessment. These workers had
an SMR of 82 for all cancers (comparing with rates for England
and Wales), whereas plutonium workers who had a plutonium dose
assessed using the standard method had an SMR of 95. We do not
believe, therefore, that the use of the two different dose assessment
methods is likely to have seriously biased the analyses.
Uptake assessments were made for 725 workers whose urine
assays were all below the limit of detection by setting the last
sample at the level of the limit applicable at that time. As well as
using the doses based on these uptake assessments, we also
conducted statistical analyses in which these workers were
assigned zero uptake (and dose). There were no material differ-
ences in the two sets of analyses.
There are further uncertainties with respect to dose estimation
because the solubility class of plutonium exposure for individual
workers at different times was unknown. We therefore assumed
both ￿W￿ and ￿Y￿ solubility classes in our analyses — this makes a
substantial difference to the estimated lung doses (see Table 2).
Many workers probably received a mixture of the two classes of
plutonium, though Y-class exposures are likely to have been most
common (Riddell et al, 1998). These and other uncertainties
complicate considerably our interpretation of analyses relating
cancer risk to estimated radiation doses from plutonium exposure.
Workers who had ever been monitored for plutonium exposure
had a cancer mortality rate similar to that of the populations of
England and Wales (SMR 100) and Cumbria (SMR 101) and a
slightly higher rate than other radiation workers (rate ratio 1.05,1300 RZ Omar et al
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Table 3), but this difference was not significantly different. The
two groups of workers also had similar cancer incidence rates (rate
ratio 0.99, Table 8). Thus, there was no evidence that, overall, the
cancer risk among plutonium workers was increased, compared
with radiation workers not monitored for exposure to plutonium.
Plutonium workers had higher death rates from breast cancer than
other radiation workers, the rate among plutonium workers being
significantly above that for England and Wales and for other radi-
ation workers being significantly below the national rate (Table 4).
Breast cancer incidence rates were also higher among plutonium
workers than other radiation workers, though not significantly so
(Table 8). All eight deaths from this cancer among radiation
workers were in women. When breast cancer risk was related to
radiation dose among plutonium workers, there was no evidence
of a dose—response relationship (Table 7), which is some evidence
against a causative association.
One woman who died of breast cancer had urine samples taken
for plutonium monitoring only after the cancer had been diagnosed
and all samples were recorded as below the limit of detection. She
was not monitored for external radiation exposure and her medical
records indicate that the urine samples were taken because of the
cancer diagnosis (AE Riddell, personal communication). If this
death is excluded from the analyses, the breast cancer mortality
rate among plutonium workers is not significantly greater than the
England and Wales rate (in Table 4: 5 observed, 2.55 expected)
and the excess among plutonium workers compared to other radia-
tion workers is of reduced significance (P < 0.05).
The only other cancer site for which plutonium workers had a
significantly higher mortality rate than other radiation workers
was for cancer of ill-defined and secondary sites (rate ratio 1.9,
Table 4), but there was not a relationship between risk and esti-
mated cumulative radiation dose among plutonium workers (Table
7). As discussed above for all radiation workers, this finding is
difficult to interpret. With respect to cancer incidence, the overall
risk for all cancers combined was similar for plutonium workers
and other radiation workers and for no individual site was there a
significant difference in the incidence rates.
The absence of any marked difference in the risks of death from
causes other than cancer between plutonium workers and other
radiation workers (Table 5) is in line with what might be expected
on the basis of previous evidence that these causes are not affected
by radiation exposure.
Organ-specific annual radiation dose estimates from plutonium
exposure were made for specific sites, as listed in Table 2. The
estimated collective cumulative doses to bone surfaces, the red
bone marrow and the liver were substantial. Those to the lung
depended greatly on whether the ￿W￿ or ￿Y￿ solubility class of
plutonium was assumed. Estimated doses to the other organs were
much lower. Among plutonium workers, we did not find any
significant positive trends between cumulative radiation doses to
different organs and the risk of death from cancer (Table 6),
though there was a significant association with cancer registrations
for all lymphatic and haematopoietic cancers combined (Table 9).
Wilkinson et al (1987), in a study of plutonium workers at the
Rocky Flats weapons facility, reported an excess of lymphopoietic
cancers among workers with body burdens of 74 Bq or greater, but
the number of cases was small and the excess was not statistically
significant.
Taken as a whole, our findings do not suggest that workers at
Sellafield who have been exposed to plutonium are at an overall
significantly increased risk of cancer, compared either with the
population of Cumbria or to other radiation workers at the plant.
Compared with the former group, there were excesses of deaths
from cancers of the pleura, breast, and ill-defined and secondary
sites, but for none of these sites was there evidence that risk was
associated with cumulative dose. Because of the indications from a
parallel study of an association between the time since first moni-
toring for plutonium and the risk of deaths from all malignant
neoplasms considered (Carpenter et al, 1998), we repeated those
analyses using our data for the Sellafield workforce. Comparing
plutonium workers with other radiation workers, the ratio of the
death rates in the two groups in the periods <10 years, 10—19 years
and ‡20 years since monitoring started were 0.82, 1.03 and 1.12.
This trend was not statistically significant [c2 (1 df trend) = 2.64].
We also found no evidence that deaths from all malignant
neoplasms were related to the number of years for which workers
had been monitored for plutonium exposure [c2 (1 df trend) = 1.27].
In a study of 15 727 men employed at the Los Alamos National
Laboratory, Wiggs et al (1994) found that no cause of death was
significantly elevated among 303 plutonium-exposed (>74 Bq)
workers when compared with other workers. They did observe,
however, a non-significant excess of lung cancers among the
former group and also a case of osteogenic sarcoma which was in
one of the 26 workers on the Manhattan project known to have been
exposed to plutonium (Voelz et al, 1997). It is notable that despite
the comparatively large radiation doses to the bone surfaces, lungs
and liver (Table 2) among Sellafield plutonium workers, no death
from bone cancer was observed, the lung cancer mortality rate was
similar to that of other radiation workers and non-radiation workers
and there was a significant deficit of deaths from liver cancer
among plutonium workers (Table 4). The results for lung cancer
contrast with those reported from a study among nuclear workers
who had been very heavily exposed to plutonium in a nuclear
facility in Russia in which a threefold excess of lung cancer was
found (147 observed, 45.4 expected) (Koshurnikova et al, 1997).
Our findings with respect to plutonium exposure must be inter-
preted with caution. Whereas external radiation doses may be esti-
mated relatively well from film badge dosimeters (Kite and
Britcher, 1996), those for internal exposures have depended
largely on monitoring urine samples and extrapolating to
organ—dose estimates based on assays of those samples. There are
several important potential sources of error in the dose-estimation
process. First, although records were available of urine samples
collected for plutonium monitoring, not all workers providing such
samples were necessarily exposed to plutonium. The sensitivity of
the assay methods to detect and measure plutonium levels varied
over time and, in particular, these were relatively poor in the early
years of the operation of the plant. Furthermore, calculation of
plutonium uptakes based on urine sample assays involves making
assumptions about patterns of exposure over time and further
assumptions are necessary to convert uptake estimates to
organ—dose. It has not been possible to determine the magnitude of
the errors that may be inherent in the dose-estimation process, but
it is considered that it would not be uncommon for them to be
lower by an order of magnitude (A. Riddell, personal communica-
tion). This limits the usefulness of quantitative dose—response
analyses. The uncertainties with respect to organ doses from pluto-
nium exposure are greatest for workers for whom urine samples
were available only prior to 1971. A reflection of the uncertainty is
that plutonium uptake estimates for this group of workers origi-
nally supplied to us by BNFL were subsequently reduced by a
factor of 3 on the basis of an internal BNFL investigation (RiddellCancer risks among plutonium workers 1301
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et al, 1998). The revised data were used in the analyses presented.
We repeated the analyses shown in Tables 7 and 9 excluding this
group of workers (who comprised 55% of all plutonium workers
for whom a standardized assessment was made). In general, the
results were not notably different from those shown in the tables.
The only exception was for cancer registrations from lung cancer,
with no lag, for which a significant trend statistic was obtained (z
= 2.25, P < 0.05). This result was based on only 20 lung cancer
registrations and no trend was apparent using lags of 10 and 20
years. Furthermore, there was no evidence of a trend with dose,
using lags of 0, 10 or 20 years, for lung cancer deaths.
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